LTR Pharma Limited LTP
ASX · Australia · Health Technology
AUD 0.4700-0.01 (-2.08%)
Market closed· · AUD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · AUD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
Shed today announced exclusive U.S. direct-to-consumer telehealth rights to ROXUS®, a rapid-acting intranasal treatment for erectile dysfunction developed by LTR Pharma. ROXUS® will be available exclusively through Mavrox, Shed's consumer-facing men's health platform.
Over the last 7 days, the Australian market has dropped 1.2%, remaining relatively flat over the past year, with earnings forecasted to grow by 12% annually. Investing in penny stocks—typically smaller or newer companies—can still open doors to growth opportunities when these stocks are backed by strong financial health. This article will explore several penny stocks that stand out as hidden gems, offering potential for impressive returns amidst current market conditions.
LTR Pharma Limited (ASX:LTP) ("LTR Pharma" or "the Company") reports interim Phase II pharmacokinetic (PK) and safety data for SPONTAN®, demonstrating a rapid time to peak concentration (median Tmax 10 minutes) and a consistent safety profile, with no serious or severe treatment-emergent adverse events observed. The data support the Company's planned FDA 505(b)(2) regulatory pathway, subject to completion of final statistical analysis.
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.